PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy

International Journal of Molecular Sciences

Volumn 15, Issue 4, 2014, Pages 6046-6061

  Rybalov, Maxim ^a   Ananias, Hildo J K ^a   Hoving, Hilde D ^a   Van Der Poel, Henk G ^b   Rosati, Stefano ^a   de Jong, Igle J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

EpCAM; GRPR; Immunohistochemistry; Prostate cancer; PSMA; VEGF

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; GASTRIN RELEASING PEPTIDE RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; VASCULOTROPIN; BOMBESIN RECEPTOR; CELL ADHESION MOLECULE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733; VASCULOTROPIN A;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; RADIATION DOSE; RETROSPECTIVE STUDY; STROMA; TUMOR BIOPSY; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TUMOR RECURRENCE; UPREGULATION;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CELL ADHESION MOLECULES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN; RETROSPECTIVE STUDIES; SALVAGE THERAPY; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898653654     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15046046     Document Type: Article

References (75)

1. Center, M.M.; Jemal, A.; Lortet-Tieulent, J.; Ward, E.; Ferlay, J.; Brawley, O.; Bray, F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012, 61, 1079-1092.
2. Kupelian, P.A.; Potters, L.; Khuntia, D.; Ciezki, J.P.; Reddy, C.A.; Reuther, A.M.; Carlson, T.P.; Klein, E.A. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 25-33.
3. Bellmunt, J.; Attard, G.; Bahl, A.; Huland, H.; Klotz, L.; Kuban, D.; Oudard, S.; Watson, W. Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int. 2012, 109, 8-13.
4. Hillier, S.M.; Maresca, K.P.; Femia, F.J.; Marquis, J.C.; Foss, C.A.; Nguyen, N.; Zimmerman, C.N.; Barrett, J.A.; Eckelman, W.C.; Pomper, M.G. et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009, 69, 6932-6940.
5. Kularatne, S.A.; Wang, K.; Santhapuram, H.K.; Low, P.S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 2009, 6, 780-789.
6. Entwistle, J.; Brown, J.G.; Chooniedass, S.; Cizeau, J.; MacDonald, G.C. Preclinical evaluation of VB6-845: An anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother. Radiopharm. 2012, 27, 582-592.
7. Köllermann, J.; Helpap, B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am. J. Clin. Pathol. 2001, 116, 115-121.
8. Ananias, H.J.; van den Heuvel, M.C.; Helfrich, W.; de Jong, I.J. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009, 69, 1101-1108.
9. Bouchelouche, K.; Choyke, P.L.; Capala, J. Prostate specific membrane antigen-A target for imaging and therapy with radionuclides. Discov. Med. 2010, 9, 55-61.
10. Ghosh, A.; Heston, W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell. Biochem. 2004, 91, 528-539.
11. Ross, J.S.; Sheehan, C.E.; Fisher, H.A.; Kaufman, R.P., Jr.; Kaur, P.; Gray, K.; Webb, I.; Gray, G.S.; Mosher, R.; Kallakury, B.V. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 2003, 9, 6357-6362.
12. Elsasser-Beile, U.; Buhler, P.; Wolf, P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr. Drug Targets 2009, 10, 118-125.
13. Bouchelouche, K.; Capala, J. "Image and treat"-An individualized approach to urological tumors. Curr. Opin. Oncol. 2010, 22, 274-280.
14. Bostwick, D.G.; Pacelli, A.; Blute, M.; Roche, P.; Murphy, G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998, 82, 2256-2261.
15. Lapidus, R.G.; Tiffany, C.W.; Isaacs, J.T.; Slusher, B.S. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000, 45, 350-354.
16. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997, 57, 3629-3634.
17. Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3, 81-85.
18. Minner, S.; Wittmer, C.; Graefen, M.; Salomon, G.; Steuber, T.; Haese, A.; Huland, H.; Bokemeyer, C.; Yekebas, E.; Dierlamm, J. et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011, 71, 281-288.
19. Rajasekaran, A.K.; Anilkumar, G.; Christiansen, J.J. Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol. Cell Physiol. 2005, 288, C975-C981.
20. Bermejo, C.E.; Coursey, J.; Basler, J.; Austenfeld, M.; Thompson, I. Histologic confirmation of lesions identified by Prostascint scan following definitive treatment. Urol. Oncol. 2003, 21, 349-352.discussion 353.
21. Lau, H.Y.; Kindrachuk, G.; Carter, M.; Prestage, K.; Webber, D.; Stauffer, E.; Haseman, M. Surgical confirmation of ProstaScint abnormalities in two patients with high risk prostate cancer. Can. J. Urol. 2001, 8, 1199-1202.
22. Hinkle, G.H.; Burgers, J.K.; Olsen, J.O.; Williams, B.S.; Lamatrice, R.A.; Barth, R.F.; Rogers, B.; Maguire, R.T. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide. J. Nucl. Med. 1998, 39, 650-652.
23. Manyak, M.J.; Hinkle, G.H.; Olsen, J.O.; Chiaccherini, R.P.; Partin, A.W.; Piantadosi, S.; Burgers, J.K.; Texter, J.H.; Neal, C.E.; Libertino, J.A. et al. Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. Urology 1999, 54, 1058-1063.
24. Taneja, S.S. ProstaScint Scan: Contemporary use in clinical practice. Rev. Urol. 2004, 6, S19-S28.
25. Trzpis, M.; McLaughlin, P.M.; de Leij, L.M.; Harmsen, M.C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171, 386-395.
26. Went, P.; Vasei, M.; Bubendorf, L.; Terracciano, L.; Tornillo, L.; Riede, U.; Kononen, J.; Simon, R.; Sauter, G.; Baeuerle, P.A. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate, and lung cancers. Br. J. Cancer 2006, 94, 128-135.
27. Van der Gun, B.T.; Melchers, L.J.; Ruiters, M.H.; de Leij, L.F.; McLaughlin, P.M.; Rots, M.G. EpCAM in carcinogenesis: The good, the bad, or the ugly. Carcinogenesis 2010, 31, 1913-1921.
28. Stoecklein, N.H.; Siegmund, A.; Scheunemann, P.; Luebke, A.M.; Erbersdobler, A.; Verde, P.E.; Eisenberger, C.F.; Peiper, M.; Rehders, A.; Esch, J.S. et al. Ep-CAM expression in squamous cell carcinoma of the esophagus: A potential therapeutic target and prognostic marker. BMC Cancer 2006, 6, 165.
29. Went, P.T.; Lugli, A.; Meier, S.; Bundi, M.; Mirlacher, M.; Sauter, G.; Dirnhofer, S. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 2004, 35, 122-128.
30. Poczatek, R.B.; Myers, R.B.; Manne, U.; Oelschlager, D.K.; Weiss, H.L.; Bostwick, D.G.; Grizzle, W.E. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol. 1999, 162, 1462-1466.
31. Varga, M.; Obrist, P.; Schneeberger, S.; Mühlmann, G.; Felgel-Farnholz, C.; Fong, D.; Zitt, M.; Brunhuber, T.; Schäfer, G.; Gastl, G. et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin. Cancer Res. 2004, 10, 3131-3136.
32. Ni, J.; Cozzi, P.J.; Duan, W.; Shigdar, S.; Graham, P.H.; John, K.H.; Li, Y. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012, 31, 779-791.
33. Patriarca, C.; Macchi, R.M.; Marschner, A.K.; Mellstedt, H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat. Rev. 2012, 38, 68-75.
34. Benko, G.; Spajić, B.; Krušlin, B.; Tomas, D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol. Oncol. 2013, 31, 468-474.
35. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 1999, 77, 527-543.
36. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9,669-676.
37. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004, 25, 581-611.
38. Kaushal, V.; Mukunyadzi, P.; Dennis, R.A.; Siegel, E.R.; Johnson, D.E.; Kohli, M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: Expression of lymphangiogenic markers is associated with advanced-stage disease. Clin. Cancer Res. 2005, 11, 584-593.
39. Peyromaure, M.; Badoual, C.; Camparo, P.; Grabar, S.; Goulvestre, C.; Fulla, Y.; Vieillefond, A.; Mao, K.; Dinh-Xuan, A.T. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer. Oncol. Rep. 2007, 18, 145-149.
40. Borre, M.; Nerstrøm, B.; Overgaard, J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res. 2000, 6, 1882-1890.
41. Jackson, M.W.; Bentel, J.M.; Tilley, W.D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol. 1997, 157, 2323-2328.
42. Ferrer, F.A.; Miller, L.J.; Andrawis, R.I.; Kurtzman, S.H.; Albertsen, P.C.; Laudone, V.P.; Kreutzer, D.L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol. 1997, 157, 2329-2333.
43. El-Gohary, Y.M.; Silverman, J.F.; Olson, P.R.; Liu, Y.L.; Cohen, J.K.; Miller, R.; Saad, R.S. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am. J. Clin. Pathol. 2007, 127, 572-579.
44. Pasquali, D.; Rossi, V.; Staibano, S.; de Rosa, G.; Chieffi, P.; Prezioso, D.; Mirone, V.; Mascolo, M.; Tramontano, D.; Bellastella, A. et al. The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy. Endocrinology 2006, 147, 4245-4251.
45. Pallares, J.; Rojo, F.; Iriarte, J.; Morote, J.; Armadans, L.I.; de Torres, I. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol. Histopathol. 2006, 21, 857-865.
46. Walsh, K.; Sriprasad, S.; Hopster, D.; Codd, J.; Mulvin, D. Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Prostate Cancer Prostatic Dis. 2002, 5, 119-122.
47. Kwak, C.; Jin, R.J.; Lee, C.; Park, M.S.; Lee, S.E. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int. 2002, 89, 303-309.
48. Strohmeyer, D.; Rössing, C.; Bauerfeind, A.; Kaufmann, O.; Schlechte, H.; Bartsch, G.; Loening, S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000, 45, 216-224.
49. Mazzucchelli, R.; Montironi, R.; Santinelli, A.; Lucarini, G.; Pugnaloni, A.; Biagini, G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000, 45, 72-79.
50. Mao, K.; Badoual, C.; Camparo, P.; Delongchamps, N.B.; Vieillefond, A.; Dinh-Xuan, A.T.; Peyromaure, M. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: A prospective evaluation in 100 patients undergoing radical prostatectomy. Can. J. Urol. 2008, 15, 4257-4262.
51. Boddy, J.L.; Fox, S.B.; Han, C.; Campo, L.; Turley, H.; Kanga, S.; Malone, P.R.; Harris, A.L. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF1a, HIF2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 2005, 11, 7658-7663.
52. Jans, J.; van Dijk, J.H.; van Schelven, S.; van der Groep, P.; Willems, S.H.; Jonges, T.N.; van Diest, P.J.; Bosch, J.L. Expression and localization of hypoxia proteins in prostate cancer: Prognostic implications after radical prostatectomy. Urology 2010, 75, 786-792.
53. Mao, K.; Camparo, P.; Badoual, C.; Peyromaure, M.; Delongchamps, N.B.; Vieillefond, A.; Dinh-Xuan, A.T. The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy. Oncol. Rep. 2008, 19, 171-175.
54. Aprikian, A.G.; Cordon-Cardo, C.; Fair, W.R.; Reuter, V.E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993, 71, 3952-3965.
55. Cutz, E.; Chan, W.; Track, N.S. Bombesin, calcitonin and leuenkephalin immunoreactivity in endocrine cells of human lung. Experientia 1981, 37, 765-767.
56. Price, J.; Penman, E.; Wass, J.A.; Rees, L.H. Bombesin-like immunoreactivity inhumangastrointestinal tract. Regul. Pept. 1984, 9, 1-10.
57. Spindel, E.R.; Chin, W.W.; Price, J.; Rees, L.H.; Besser, G.M.; Habener, J.F. Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc. Natl. Acad. Sci. USA 1984, 81, 5699-5703.
58. Track, N.S.; Cutz, E. Bombesin-like immunoreactivity in developing human lung. Life Sci. 1982, 30, 1553-1556.
59. Xiao, D.; Wang, J.; Hampton, L.L.; Weber, H.C. The human gastrinreleasing peptide receptor gene structure, its tissue expression and promoter. Gene 2001, 264, 95-103.
60. Beer, M.; Montani, M.; Gerhardt, J.; Wild, P.J.; Hany, T.F.; Hermanns, T.; Müntener, M.; Kristiansen, G. Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates. Prostate 2012, 72, 318-325.
61. Bartholdi, M.F.; Wu, J.M.; Pu, H.; Troncoso, P.; Eden, P.A.; Feldman, R.I. In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int. J. Cancer 1998, 79, 82-90.
62. Markwalder, R.; Reubi, J.C. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. Cancer Res. 1999, 59, 1152-1159.
63. Bologna, M.; Festuccia, C.; Muzi, P.; Biordi, L.; Ciomei, M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989, 63, 1714-1720.
64. Shimoda, J. Effects of bombesin and its antibody on growth of human prostatic carcinoma cell lines. Nihon Hinyokika Gakkai Zasshi 1992, 83, 1459-1468.
65. Zellweger, T.; Ninck, C.; Bloch, M.; Mirlacher, M.; Koivisto, P.A.; Helin, H.J.; Mihatsch, M.J.; Gasser, T.C.; Bubendorf, L. Expression patterns of potential therapeutic targets in prostate cancer. Int. J. Cancer 2005, 113, 619-628.
66. Li, R.; Younes, M.; Wheeler, T.M.; Scardino, P.; Ohori, M.; Frolov, A.; Ayala, G. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004, 58, 193-199.
67. Inoue, Y.; Ojima, E.; Watanabe, H.; Hiro, J.; Toiyama, Y.; Kobayashi, M.; Miki, C.; Kusunoki, M. Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer? Oncol. Rep. 2007, 18, 369-375.
68. Bellone, S.; Siegel, E.R.; Cocco, E.; Cargnelutti, M.; Silasi, D.A.; Azodi, M.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Santin, A.D. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-specific immunotherapy. Int. J. Gynecol. Cancer 2009, 19, 860-866.
69. Koomagi, R.; Zintl, F.; Sauerbrey, A.; Volm, M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin. Cancer Res. 2001, 7, 3381-3384.
70. Ananias, H.J.; de Jong, I.J.; Dierckx, R.A.; van de Wiele, C.; Helfrich, W.; Elsinga, P.H. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr. Pharm. Des. 2008, 14, 3033-3047.
71. Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S. et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 486-495.
72. Cho, S.Y.; Gage, K.L.; Mease, R.C.; Senthamizhchelvan, S.; Holt, D.P.; Jeffrey-Kwanisai, A.; Endres, C.J.; Dannals, R.F.; Sgouros, G.; Lodge, M. et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 2012, 53, 1883-1891.
73. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008, 49, 113S-128S.
74. Hsieh, W.J.; Liang, C.J.; Chieh, J.J.; Wang, S.H.; Lai, I.R.; Chen, J.H.; Chang, F.H.; Tseng, W.K.; Yang, S.Y.; Wu, C.C. et al. In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int. J. Nanomed. 2012, 7, 2833-2842.
75. Song, Y.; Zhu, Z.; An, Y.; Zhang, W.; Zhang, H.; Liu, D.; Yu, C.; Duan, W.; Yang, C.J. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal. Chem. 2013, 85, 4141-4149.